AI product management · Industry brief

Datavault AI (NASDAQ: DVLT) announced a non-binding letter of intent to acquire a 19.9% equity stake in DataMEDS AI (NASDAQ: MEDS) in exchange for expanding its existing technology license. Under the proposed deal, Datavault AI will license its Datavault AI Health capabilities for patient-controlled health data access, monetization, and tokenization across pharmacy, laboratory, wearable, and commercial healthcare environments, while retaining ownership of underlying intellectual property and gaining the right to designate one board director at DataMEDS. The transaction follows FDA guidance on regulatory considerations for prescription drug use-related software and involves multiple parties including EOS Technology Holdings, Scilex Holding Company, HealthBridge Advisors, and REBOOT Health AI. The announcement was published October 22, 2026 via Business Wire.

California's SB 923 expands CCPA deletion rights to all personal information held by businesses, including third-party data and inferences, with an effective date of January 1, 2027. New York has three AI bills pending gubernatorial action covering training data transparency (A 6578-B / S 6955-A), deepfake content provenance (S 6954-B / A 6540-E), and surveillance-based pricing (A 9349-B / S 8623-B), plus chatbot-toy restrictions for children under 12. Delaware lowered its PDPA applicability thresholds from 35,000 to 10,000 consumers and expanded sensitive data definitions to include neural data and financial credentials, effective January 1, 2027. California, Illinois, and New York have enacted frontier AI laws with compute-based coverage and incident reporting requirements, with similar proposals pending in Massachusetts and Pennsylvania, while a federal FRONTIER Act remains under consideration.

Two significant securities class action lawsuits filed in October 2026 exemplify a surge in AI-related securities litigation. Alphabet faces a complaint filed October 2, 2026, in the Northern District of California alleging the company misrepresented the capabilities and launch timeline of its Gemini 3.5 Pro product, claiming executives failed to disclose disappointing training results and significant delays between May 19 and June 16, 2026 (Northern District of California docket). Duolingo faces a complaint filed October 7, 2026, in the Western District of Pennsylvania alleging executives concealed negative impacts from aggressive monetization and integration of lower-quality AI-generated content while assuring investors of sustainable growth, covering the period from May 2, 2025, through February 26, 2026 (Western District of Pennsylvania docket). Both cases allege violations of Securities Exchange Act Sections 10(b) and 20(a) and Rule 10b-5. The filings reflect a dramatic increase in AI-related securities litigation—30 cases filed year-to-date in 2026 compared to 16 total in 2025—with the SEC also initiating three AI-related enforcement actions in August and September 2026 focused on companies' claims regarding AI use to attract investors.